Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | GLP1R | P43220 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912076 | 0.93 | CASP2 (0.66) | CASP2EPHX2NAAAHPGDFAAH | |
| SCHEMBL8251628 | 0.91 | CASP2 (0.63) | CASP2EPHX2NAAAHPGDFAAH | |
| SCHEMBL29649487 | 0.90 | MEN1 (0.54) | CASP2EPHX2NAAAMEN1MAPT | |
| SCHEMBL12508016 | 0.90 | CASP2 (0.61) | CASP2EPHX2NAAAHPGDFAAH | |
| SCHEMBL31027942 | 0.89 | EPHX2 (0.48) | CASP2EPHX2MEN1MAPTKMT2A | |
| SCHEMBL24668076 | 0.89 | EPHX2 (0.47) | EPHX2MEN1MAPTKMT2ASLC6A5 | |
| SCHEMBL23340012 | 0.88 | EPHX2 (0.41) | CASP2EPHX2NAAAMEN1MAPT | |
| SCHEMBL25574266 | 0.88 | CASP2 (0.63) | CASP2EPHX2NAAAHPGDFAAH | |
| SCHEMBL23339523 | 0.88 | EPHX2 (0.41) | CASP2EPHX2NAAAMEN1MAPT | |
| SCHEMBL24894308 | 0.88 | CASP2 (0.45) | CASP2EPHX2NAAAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4048315-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | CASP2 3264/4885EPHX2 95/4885NAAA 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.